Side-by-side comparison of AI visibility scores, market position, and capabilities
Alveus Therapeutics raised $150M Series A in 2025 for inhaled mRNA therapeutics targeting pulmonary diseases including idiopathic pulmonary fibrosis and COPD, bringing mRNA technology directly to the lung.
Alveus Therapeutics is applying mRNA medicine to pulmonary diseases by developing inhaled mRNA formulations that deliver protein replacement or gene editing instructions directly to lung cells. Unlike systemic mRNA therapeutics that require IV infusion and liver targeting, Alveus's inhaled approach delivers mRNA locally to lung epithelial cells, enabling treatment of diseases like idiopathic pulmonary fibrosis (IPF), COPD, and cystic fibrosis with potentially lower doses and fewer systemic side effects.
Raised $115M (Feb 2026) led by General Atlantic. Post-merger with Soli Organic creates largest indoor farm in North America. ~$200M combined first-year revenues.
80 Acres Farms is a commercial-scale indoor vertical farming company that, following its merger with Soli Organic, operates the largest indoor farming network in North America. The company raised $115 million in February 2026 led by General Atlantic, with projected first-year combined revenues approaching $200 million — making it one of the few vertical farming companies to achieve genuine commercial scale after years of industry attrition that eliminated several high-profile competitors.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.